Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure by Fröhlich, Hanna et al.
 
 
 
 
Fröhlich, H. et al. (2017) Statins attenuate but do not eliminate the reverse 
epidemiology of total serum cholesterol in patients with non-ischemic 
chronic heart failure. International Journal of Cardiology, 238, pp. 97-104. 
(doi:10.1016/j.ijcard.2017.03.028) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/138583/ 
     
 
 
 
 
 
 
Deposited on: 29 March 2017 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
1 
 
Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in 
patients with non-ischemic chronic heart failure 
Authors: Hanna Fröhlicha, MD; Nandita Ramana; Tobias Tägera, MD; Dieter Schellberga, MS; Kevin 
M. Goodeb, MD; Syed Kazmib, MS; Morten Grundtvigc, MD; Torstein Holed, MD; John G. F. 
Clelande, Prof.; Hugo A. Katusa, Prof.; Stefan Agewallf, Prof.; Andrew L. Clarkb, Prof.; Dan Atarf, 
Prof.; Lutz Frankensteina, Prof.  
aUniversity Hospital Heidelberg, Department of Cardiology, Angiology and Pulmology. Im 
Neuenheimer Feld 410, 69221 Heidelberg, Germany. This author takes responsibility for all aspects of 
the reliability and freedom from bias of the data presented and their discussed interpretation. 
bCastle Hill Hospital of the University of Hull, Cottingham, HU165JQ, United Kingdom. This author 
takes responsibility for all aspects of the reliability and freedom from bias of the data presented and 
their discussed interpretation.  
cMedical Department, Innlandet Hospital Trust Division Lillehammer, Anders Sandvigs gate 17, 2609 
Lillehammer, Norway. This author takes responsibility for all aspects of the reliability and freedom 
from bias of the data presented and their discussed interpretation. 
dMedical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway & 
Medical Clinic, Helse Møre and Romsdal CHF, Åsehaugen 1, 6017 Ålesund, Norway. This author 
takes responsibility for all aspects of the reliability and freedom from bias of the data presented and 
their discussed interpretation.  
eNational Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, SW72AZ 
London, United Kingdom. This author takes responsibility for all aspects of the reliability and freedom 
from bias of the data presented and their discussed interpretation. 
fDepartment of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, 
University of Oslo, Kirkeveien 166, 0450 Oslo, Norway. This author takes responsibility for all 
aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. 
 
  
2 
 
Corresponding author: 
Prof. Dr. med. Lutz Frankenstein 
Im Neuenheimer Feld 410 
69120 Heidelberg 
Germany 
Phone: 0049-6221-56-38895 
Fax: 0049-6221-56-33575 
Email: lutz.frankenstein@med.uni-heidelberg.de 
Grant support/ Funding: This research did not receive any specific grant from funding agencies in 
the public, commercial, or not-for-profit sectors. 
Conflicts of interest: Dr. Agewall reports personal fees from Advisory Board AstraZeneca, personal 
fees from Advisory Board Vifor, personal fees from Advisory Board Thermo Fischer Scientific, 
outside the submitted work. 
Keywords: serum cholesterol, statins, reverse epidemiology, chronic heart failure, prognosis  
Abbreviations: chronic heart failure (CHF), total serum cholesterol (TC), low-density lipoprotein 
cholesterol (LDL)  
3 
 
Abstract 
Background: In patients with chronic heart failure (CHF) increasing levels of total serum cholesterol 
are associated with improved survival – while statin usage is not. The impact of statin treatment on the 
“reverse epidemiology” of cholesterol is unclear.   
Methods: 2,992 consecutive patients with non-ischemic CHF due to left ventricular systolic 
dysfunction from the Norwegian CHF Registry and the CHF Registries of the Universities of Hull, 
UK, and Heidelberg, Germany, were studied. 1,736 patients were individually double-matched on 
both cholesterol levels and the individual propensity scores for statin treatment. All-cause mortality 
was analyzed as a function of baseline cholesterol and statin use in both the general and the matched 
sample.  
Results: 1,209 patients (40.4%) received a statin. During a follow-up of 13,740 patient-years, 360 
statin users (29.8%) and 573 (32.1%) statin non-users died. When grouped according to total 
cholesterol levels as low (≤3.6mmol/L), moderate (3.7-4.9mmol/L), high (4.8-6.2mmol/L), and very 
high (>6.2mmol/L), we found improved survival with very high as compared with low cholesterol 
levels. This association was present in statin users and non-users in both the general and matched 
sample (p<0.05 for each group comparison). The negative association of total cholesterol and 
mortality persisted when cholesterol was treated as a continuous variable (HR 0.83, 95%CI 0.77-0.90, 
p<0.001 for matched patients), but it was less pronounced in statin users than in non-users (F-test 
p<0.001). 
Conclusions: Statins attenuate but do not eliminate the reverse epidemiological association between 
increasing total serum cholesterol and improved survival in patients with non-ischemic CHF. 
Words: 245 
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1. Introduction 
Hypercholesterolemia is an established risk factor for the development of both cardiovascular disease 
and chronic heart failure (CHF) (1-3). In the general population, treatment of hypercholesterolemia 
with statins is effective in the primary and secondary prevention of major cardiovascular events, 
particularly when achieving very low levels of serum cholesterol (1, 2, 4). In patients with CHF, 
however, the prognostic significance of hypercholesterolemia seems to change: numerous 
observational studies have found that low values of total serum cholesterol (TC) and low-density 
lipoprotein cholesterol (LDL) are associated with worse rather than better survival in patients with 
CHF (5-15). This counterintuitive risk inversion has been referred to as “reverse epidemiology” (13). 
It has been observed in both patients with acute and with chronic CHF of ischemic and non-ischemic 
origin (5-13). Conversely, lipid-lowering therapy with statins seems to be of no benefit in patients with 
CHF (1, 2, 16, 17).  
It is unclear to what extent treatment with statins contributes to the reverse epidemiology of serum 
lipids in CHF (8, 10, 12, 18). On the one hand, statins lower TC levels which might be beneficial, yet 
in patients with CHF, lower cholesterol levels may convey adverse prognosis. We therefore aimed to 
investigate the relative effects of statin treatment and TC levels on survival in a large international 
cohort of patients with non-ischemic CHF due to left ventricular systolic dysfunction. 
 
2. Material and Methods 
2.1. Databases 
Patients’ data were extracted from three different European CHF registries: the Norwegian Heart 
Failure Registry, the Heart Failure Registry of the Department of Academic Cardiology, University of 
Hull, United Kingdom, and the Heart Failure Registry of the University of Heidelberg, Germany. 
Recruitment was prospective and continuous for each database and center. All patients gave their 
written informed consent for data storage and evaluation. The study conformed to the principles 
outlined in the Declaration of Helsinki and was approved by the local ethics committees.  
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The Norwegian Heart Failure Registry was initiated in October 2000 and patients were enrolled from 
outpatients’ clinics of 27 recruiting hospitals well-distributed in all regions of Norway ranging in size 
and scope from small community to large university hospitals. The participating centers recorded their 
data using a web-based database. 
Patients who attended the community heart failure clinics of the University of Hull, UK, and the 
University of Heidelberg, Germany, for evaluation of CHF were offered inclusion into the local CHF 
registries. The registries were initiated in 1999 and 1996, respectively. Since both university hospitals 
serve as primary health care centers as well as tertiary referral centers, the registries reflect a broad 
representation of patients of their respective regions. 
2.2. Patient selection and follow-up 
Patients were eligible for this study if they met all of the following criteria: a) attendance at the CHF 
outpatients’ clinic of any of the participating hospitals, b) written informed consent for inclusion into 
the respective CHF registry, c) history of non-ischemic CHF due to left ventricular systolic 
dysfunction, and d) TC levels and medication recorded at the inclusion visit.  
The diagnosis of CHF was established according to guidelines on the basis of typical symptoms and 
signs resulting from an objective abnormality of cardiac structure or function on echocardiography, 
cardiac magnetic resonance imaging, or left heart catheterization (19). Non-ischemic origin of CHF 
was verified by absence of a medical history of coronary heart disease or angina pectoris and absence 
of Q-waves from the electrocardiogram. When required, cardiac computer tomography, cardiac 
magnetic resonance imaging, or left heart catheterization was performed to exclude significant 
coronary heart disease. All included patients had a left ventricular ejection fraction <45%. Medication 
was at the discretion of the referring physician with respect to guideline recommended drugs. 
Surviving patients were followed up for a minimum of six months. Determination of survival status 
and follow-up were performed by scheduled visits to the outpatients’ clinic, by telephone calls either 
to the patients’ homes or to their physicians, or by electronic hospital records. In addition, for the 
Norwegian Heart Failure Registry mortality data were obtained at regular intervals from the National 
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Statistics Bureau, Statistics Norway. All-cause mortality was the pre-defined endpoint for the purpose 
of the analysis.  
2.3. Statistical analysis 
Calculations were performed using IBM SPSS statistics 20 (IBM, Ehningen, Germany) and MedCalc 
Statistical Software version 14.12.0 (MedCalc Software bvba, Ostend, Belgium). Graphs were 
displayed using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California 
USA). 
All tests are two-tailed and a P-value of less than 5% was regarded as being statistically significant. 
Variables are presented as mean±standard deviation, median (interquartile range), or number 
(percentages; %) as appropriate. Chi-squared test was used to compare frequencies. To test for 
significant differences between groups, the two-sample Wilcoxon test and Student’s t test were used 
where appropriate. Differences in event-free survival were analyzed using Cox proportional hazard 
models and displayed using the Kaplan-Meier method for survival.  
In order to analyze the relative effects of TC and statin treatment on survival, different strategies were 
applied:  
First, survival was analyzed with respect to statin treatment in a univariable Cox regression analysis of 
the general sample. Then, patients were classified into 4 groups according to their TC at the inclusion 
visit defined as low (TC1 ≤3.6mmol/L), moderate (TC2 3.7-4.9mmol/L), high (TC3 5.0-6.2mmol/L), 
and very high (TC4 >6.2mmol/L) TC. The graduation into 4 groups was chosen as a trade-off between 
sufficiently large a group size and enough groups to demonstrate the potential relationship between TC 
level and survival. Survival was compared between TC groups in the general sample, in patients 
treated with statins and in patients without statin therapy. In addition, survival within each TC group 
was analyzed with respect to statin treatment.  
Second, TC was treated as a continuous variable, and the impact of TC on mortality was analyzed 
using Cox regressions. Again, analyses were performed in the general sample, in statin users and non-
statin users. 
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Third, to account for possible confounders, a propensity score for the conditional probability of 
receiving a statin was derived for each patient. The propensity score was calculated as the single 
composite variable from a non-parsimonious multivariate logit-linked binary logistic regression of all 
baseline characteristics. The propensity score may be used to balance covariates, and numerous studies 
have reported that it is an adequate tool to reduce bias in observational studies (20-22). Statin 
treatment was the dependent variable (23). The logit of the probability of receiving a statin according 
to the score formed the basis of our matching procedure. Patients were individually matched on both 
the propensity of receiving a statin AND their TC levels. The matching procedure was performed in 
two steps: firstly, caliper matching of the propensity score was applied with caliper size predefined as 
0.2 of the standard deviation of the total sample (24). In a one-pass procedure starting with a given 
patient receiving a statin, the closest match of a patient without statin therapy was identified. 
Secondly, TC levels were compared. If TC levels varied ≤10%, the pair of patients was retained for 
analysis and removed from the total sample to allow for the next matching cycle to take place. If TC 
levels varied >10%, the pair was rejected. Then the first step of the matching process was repeated to 
identify the next closest match to the statin patients of the failed matched according to the propensity 
score. If a further patient without statin treatment was thus identified, the second step was repeated. In 
cases where we could find no match according to the propensity score AND TC level, the statin 
patient was removed from the total sample and the matching cycle started with the next statin patient. 
All survival analyses were repeated in the matched sample. In addition, binary logistic regressions 
were performed to analyze the impact of TC on five-year mortality in matched statin users and non-
users. For graphic display, the logits of the regression models were used to calculate the relative 
probability of five-year death of each matched patient (statin users and non-users) with respect to TC 
levels following: probit = 1/(1+e^-logit). Curves were compared using the sum-of-squares F-test. 
As a sensitivity analysis, the association of statin treatment, TC and mortality was analyzed in the 
general sample using stepwise multivariable Cox regression analyses. Variables that were significant 
in univariable analyses of the baseline characteristics were entered as covariates. Analyses were 
repeated in subgroups of statin users and non-users. In addition, as patients in the propensity score 
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matched cohort differed with respect to age and country, survival analyses were repeated in the 
matched sample after adjusting for age and country using multivariable Cox regression analyses. 
Again, analyses were repeated in subgroups of statin users and non-users. 
 
3. Results 
3.1. Patient characteristics and follow-up 
We identified a total of 2,992 patients who met the inclusion criteria outlined above. Of these, 1,616 
(54.0%), 893 (29.8%), and 483 (16.1%) patients were included from the Norwegian Heart Failure 
Registry, the Heart Failure Registry of the University of Heidelberg, and the Heart Failure Registry of 
the University of Hull, respectively. A total of 1,209 patients (40.4%) was treated with a statin. Mean 
TC in patients without statin treatment was 5.2±1.3mmol/L, while it was 4.8±1.3mmol/L in patients 
taking statins (p<0.001).  Overall, patients on statins were older and more likely to suffer from co-
morbidities such as arterial hypertension and diabetes mellitus than patients without statin treatment. 
Baseline characteristics of the complete patient sample with respect to statin treatment are shown in 
table 1.  
Total follow-up was 13,740 patient-years with a mean follow-up duration of 51.1±35.3 months 
(4.26±2.94 years). During that time, a total of 933 patients (31.2%) died, 390 (29.8%) in the statin 
group and 573 (32.1%) in the non-statin group.  
3.2. Prognostic significance of statin treatment and TC in the general sample 
In univariable Cox regression analysis of the complete sample, treatment with statins was not 
associated with improved survival (HR 0.96, 95% CI 0.84-1.10, p=0.59 for use) (figure 1). When 
individual TC groups were analyzed separately, survival within each TC group was again not affected 
by statin treatment (HR 1.07, 95% CI 0.77-1.48, p=0.68; HR 0.84, 95% CI 0.67-1.04, p=0.11; HR 
0.95, 95% CI 0.75-1.21, p=0.70; and HR 0.94, 95% CI 0.65-1.37, p=0.76 for use in TC1, TC2, TC3, 
and TC4, respectively).  
9 
 
Mortality was significantly lower in patients with moderate, high or very high TC levels as compared 
to patients with low TC levels. This was true for patients on statins as well as for patients without 
statin therapy. In patients without statin treatment, however, there was no difference in survival 
between patients with low and patients with moderate TC levels (figures 2 and 3).  
When treating TC as a continuous variable, Cox regression analyses found a significant negative 
association between TC and all-cause mortality in the general sample, in statin users and statin non-
users (HR 0.89, 95% CI 0.85-0.94, p<0.001; HR 0.87, 95% CI 0.80-0.94, p<0.001; and HR 0.90, 95% 
CI 0.84-0.96, p=0.001, respectively). 
3.3. Prognostic significance of statin treatment and TC in the matched sample 
The matching procedure identified 868 pairs of statin/non-statin patients with equal TC levels and 
equal probability of receiving a statin. The matching significantly reduced standardized differences 
below 10 % in the absolute values for the majority of observed covariates, demonstrating a substantial 
improvement in the covariate balance across the treatment groups. The baseline characteristics of the 
matched cohort are shown in table 2.  
The analyses in the matched sample confirmed those from the general sample. Again, treatment with 
statins was not associated with improved survival in either the complete matched sample (HR 0.90, 
95% CI 0.75-1.07, p=0.24), or in the respective matched TC groups (HR 0.97, 95% CI 0.64-1.46, 
p=0.87; HR 0.78, 95% CI 0.59-1.03, p=0.07; HR 0.91, 95% CI 0.66-1.25, p=0.56; and HR 1.23, 95% 
CI 0.71-2.13, p=0.46 for use in TC1, TC2, TC3, and TC4, respectively). 
As in the general sample, mortality was lower in matched patients with moderate, high, or very high 
TC levels as compared with matched patients with low TC levels (figure 4). Again, the association 
was seen in patients on statins as well as in patients without statin therapy, with the exception that in 
patients without statin therapy, survival did not differ between low and moderate TC levels (figure 5-
8).  
Treating TC as a continuous variable confirmed the negative relationship between TC and all-cause 
patients mortality in matched CHF patients (HR 0.83, 95%CI 0.77-0.90, p<0.001). The association 
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was less pronounced in matched patients with statin treatment as compared to non-users (HR 0.85, 
95% 0.77-0.95, p=0.004; and HR 0.81, 95% CI 0.73-0.90, p=0.0001 for statin users and non-users, 
respectively). 
Similarly, logistic regression analysis showed a significant inverse relationship between TC and five-
year mortality in the common matched sample (OR 0.81, 95% CI 0.74-0.90, p<0.001), in matched 
statin users (OR 0.83, 95% CI 0.72-0.96, p=0.01), and non-users (OR 0.79, 95%CI 0.69-0.91, 
p=0.001). The slope of the respective probability plots was less pronounced in statin users than in 
statin non-users (p<0.001). The probability of five-year death with respect to TC levels and statin 
treatment for matched CHF patients is displayed in figure 6. 
3.4. Sensitivity analyses 
Multivariable analyses of both the general and the matched sample confirmed the results from the 
main analyses: In stepwise multivariable Cox regression analyses of the general sample including 
significant variables from univariable analyses, statin treatment was not associated with survival 
(p=0.12), while increasing levels of TC were associated with better survival (HR 0.89, 95% CI 0.81-
0.97, p=0.009). This was true in statin users (HR 0.86, 95%CI 0.74-0.99, p=0.049) and non-users (HR 
0.87, 95%CI 0.77-0.98, p=0.02).  
Similarly, stepwise multivariable Cox regression analyses of the matched sample including age and 
country as covariates did not find a relationship between statin treatment and survival (HR 0.88, 
95%CI 0.74-1.05, p=0.14). Increasing levels of TC were associated with better survival in all matched 
patients (HR 0.83, 95% CI 0.77-0.90, p<0.0001), matched statin users (HR 0.86, 95% CI 0.77-0.96, 
p=0.006) and matched non-users (HR 0.80, 95%CI 0.72-0.89, p<0.0001). Again, the relationship 
between TC and survival was less pronounced in statin users than in statin non-users. 
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4. Discussion 
We investigated the relative effects of statin treatment and TC levels on survival in an international 
sample of ambulatory patients with chronic CHF not due to ischemic heart disease. We observed a 
“reverse epidemiological” association between increasing TC and better survival irrespective of statin 
therapy where low TC levels were associated with worse survival as compared with moderate, high, or 
very high TC concentrations. Although statin therapy did not affect survival, statins attenuated the 
strength of the inverse association between TC and outcome. 
Statins have become the most important lipid lowering medications with proven efficacy in the 
treatment of hyperlipidemia (1, 2). In addition to lowering cholesterol, statins appear to have 
pleiotropic effects which might influence pathophysiology and could potentially confer benefits on 
patients with CHF (25-27). The beneficial effects of statins have been attributed to their anti-
inflammatory properties, and their counter-regulatory actions on the renin–angiotensin–aldosterone 
and sympathetic systems as well as on the mechanisms of cardiac hypertrophy and fibrosis (26).  
Treatment with statins in patients with CHF has been associated with reduced hospital admissions and 
mortality in several non-randomized studies (25, 28-31), post-hoc analyses (32, 33) and meta-analyses 
of randomized trials (34-36). The two largest randomized trials – the Controlled Rosuvastatin 
Multinational Study in Heart failure (CORONA) (16) and the Gruppo Italiano per lo Studio della 
Sopravvivenza Nell’Insufficienza Cardiaca Heart Failure study (GISSI-HF) (17) – however, failed to 
show a survival benefit of statins in patients with CHF. Current European guidelines therefore advise 
against statin therapy as a CHF treatment (1). The results of our study support this recommendation 
for patients with CHF due to non-ischemic etiologies, since survival was similar irrespective of statin 
treatment in both the general and the matched sample.  
Our study also confirms the reverse epidemiological association between TC and survival in patients 
with chronic CHF. The phenomenon has been reported from numerous observational studies and post-
hoc analyses (5-15), and it has also been described for other cardiovascular risk factors such as obesity 
and hypertension (11, 13). The mechanisms underlying the risk inversion of classical risk factors in 
chronic CHF are presently unclear. In recent years, a number of plausible hypotheses has been 
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proposed (13, 37-40) including the malnutrition–inflammation complex syndrome (13, 40) or theories 
focusing on endotoxin lipoproteins (37), ubiquinone (38), and selenoproteins (39).  
Data regarding the influence of statin therapy on the reverse epidemiology are scarce. Silva et al. 
suggested that the low TC levels were not causally related to worse survival but simply represented an 
advanced stage of CHF. In a retrospective cohort study of 464 ambulatory CHF patients, they found 
that only patients with intrinsically low TC concentrations (<3.9mmol/L) were at increased risk of 
death, while outcomes were best in CHF patients with pharmacologically induced low TC (12) – thus 
effectively arguing against the presence of reverse epidemiology in patients on statin therapy. 
Similarly, an Israeli study of 297 patients with advanced CHF reported that the negative association 
between LDL cholesterol level and mortality was only present in patients taking statins (18). In 
contrast, Kahn et al. reported that treatment with statins did not impact the reverse epidemiology of 
LDL in a study of 2,428 patients with acute CHF. (8). 
In agreement with Kahn et al., we observed that low TC levels were associated with increased 
mortality as compared with high and very high TC levels irrespective of statin treatment. However, 
statins seem to attenuate the extent of risk inversion, since the negative relationship between TC and 
mortality was more pronounced in non-statin users. Whether this risk modulation is mediated by 
pleiotropic effects of statins remains speculative.  Prospective trials are warranted to clarify the nature 
of risk inversion in CHF, the role of statins and possible treatment targets. 
 
5. Limitations 
A potential limitation to the present study is its observational design, implying the possibility of 
selection bias and unadjusted confounding. In addition, since matching was performed after treatment 
allocation, the relation between statin therapy, TC and all-cause mortality is associative, not causal. 
However, our data result from large comprehensive outpatient databases with continuous inclusion 
and close surveillance. Our study adds significant evidence to current knowledge by providing a large 
international patient cohort with a long follow-up and a robust statistical analysis. Notably, the 
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presence of a reverse epidemiology of TC irrespective of statin treatment was established in 
univariable and multivariable regression analyses of both the general and the matched sample. Our 
data reflect the effects of TC levels and statin therapy in real-world patients in contrast to randomized 
trials. Our findings are clinically relevant to the population at interest given the known differences 
between study cohorts and “real world” patients.  
We chose to restrict our analysis to patients with non-ischemic CHF since patients with ischemic CHF 
are usually treated with statins for coronary heart disease. Not only would this have hampered 
adequate matching to patients without statin therapy but the intrinsic prognostic benefit in coronary 
artery disease is unquestioned. A recently published observational study of 21,864 patients reported 
improved outcomes in statin users with CHF due to ischemic heart disease (31). Our results will 
therefore not be transferable to patients with CHF of ischemic origin. In addition, the classification as 
non-ischemic CHF may have been inexact in some patients since left heart catheterization was not 
performed in all patients. However, other studies observed a reverse epidemiology of TC in both 
ischemic and non-ischemic CHF (5, 7, 8, 10-12). 
The present study was limited by not having information on LDL levels. However, the “reverse 
epidemiology” has been reported for LDL as well as TC (5-15), and statins similarly affect both LDL 
and TC levels (41, 42). Therefore, it is likely that our results may be transferred to LDL 
measurements. 
This study was further limited by not having information on the type of statin that was used in 
patients. As pharmacokinetics of lipophilic statins may differ from that of hydrophilic statins, a 
differential effect of certain statins cannot be ruled out (43, 44). Moreover, we cannot comment on 
medication adherence. Statin therapy may have been stopped during the course of follow-up. 
However, inclusion into the analyses of our study was performed after stabilization of both clinical 
status and medication in an ambulatory setting. This may reduce the necessity for further modulation 
of statin treatment. 
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Figure legends 
Figure 1 
Title: Kaplan–Meier curves for 10-year survival for chronic heart failure outpatients with respect to 
statin treatment 
Legend: Small numbers indicate the numbers at risk at the respective follow-up. 
 
Figure 2:  
Title: Forrest plot for Cox regression analyses for all-cause mortality in the general cohort, in patients 
with statin treatment and in patients without statin treatment with respect to total serum cholesterol 
levels. 
Legend: TC1, total serum cholesterol ≤3.6mmol/L; TC2, total serum cholesterol 3.7-4.9mmol/L; TC3, 
total serum cholesterol 5.0-6.2mmol/L; TC4, total serum cholesterol >6.2mmol/L; HR, hazard ratio; 
CI, confidence interval. 
 
Figure 3 a) and b) 
Title: Kaplan–Meier curves for 10-year survival for chronic heart failure outpatients a) with statin 
treatment, and b) without statin treatment with respect to total serum cholesterol levels. 
Legend: TC1, total serum cholesterol ≤3.6mmol/L; TC2, total serum cholesterol 3.7-4.9mmol/L; TC3, 
total serum cholesterol 5.0-6.2mmol/L; TC4, total serum cholesterol >6.2mmol/L.Small numbers 
indicate the numbers at risk at the respective follow-up. 
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Figure 4:  
Title: Cox regression analyses for all-cause mortality in the matched cohort, in matched patients with 
statin treatment and in matched patients without statin treatment with respect to total serum cholesterol 
levels. 
Legend: TC1, total serum cholesterol ≤3.6mmol/L; TC2, total serum cholesterol 3.7-4.9mmol/L; TC3, 
total serum cholesterol 5.0-6.2mmol/L; TC4, total serum cholesterol >6.2mmol/L; HR, hazard ratio; 
CI, confidence interval. 
 
Figure 5 a) and b) 
Title: Kaplan–Meier curves for 10-year survival for matched chronic heart failure outpatients a) with 
statin treatment and b) without statin treatment with respect to total serum cholesterol levels. 
Legend: TC1, total serum cholesterol ≤3.6mmol/L; TC2, total serum cholesterol 3.7-4.9mmol/L; TC3, 
total serum cholesterol 5.0-6.2mmol/L; TC4, total serum cholesterol >6.2mmol/L. Small numbers 
indicate the numbers at risk at the respective follow-up. 
 
 
 
Figure 6 
Title: Probability of five-year death in matched chronic heart failure patients with respect to total 
serum cholesterol levels and statin treatment 
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Table 1: Baseline characteristics for the complete cohort and separate with respect to statin treatment 
Characteristic 
All patients  
(n=2,992) 
No statin  
(n=1,783) 
P-
value 
Statin  
(n=1,209) 
Age, years 63.8±15.0 62.2±16.2 <0.001 65.5±12.9 
Male, n (%) 2,025 (67.7) 1,176 (66.0) 0.014 849 (70.2) 
Aetiology, n (%)   0.25  
DCM 1,569 (52.4) 953 (53.4)  616 (51.0) 
Hypertensive 383 (12.8) 233 (13.1)  150 (12.4) 
Valvular 260 (8.7) 156 (8.7)  104 (8.6) 
Other 780 (26.1) 441 (24.7)  339 (28.0) 
NYHA, n (%)   0.003  
I 659 (22.2) 418 (23.7)  241 (20.2) 
II 1,505 (50.8) 914 (51.8)  591 (49.4) 
III 777 (26.2) 422 (23.9)  355 (29.7) 
IV 21 (0.7) 12 (0.7)  9 (0.8) 
SBP, mmHg 124±22 124±23 0.42 125±22 
HR, 1/min 70±14 71±15 0.015 70±13 
BMI, kg/m² 27.3±5.4 27.1±5.5 0.015 27.6±5.3 
LVEF, % 34±14 35±14 0.19 34±14 
Co-morbidity     
aHT, n (%) 1,303 (43.5) 738 (41.4) 0.004 565 (46.7) 
COPD, n (%) 489 (16.3) 285 (16.0) 0.52 204 (16.9) 
Diabetes, n (%) 449 (15.0) 215 (12.1) <0.001 234 (19.4) 
Smoker, n (%) 432 (14.4) 249 (14.0) 0.45 183 (15.1) 
Country, n (%)   <0.001  
Norway 1,616 (54.0) 878 (49.2)  738 (61.0) 
Germany 893 (29.8) 562 (31.5)  331 (27.4) 
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UK 483 (16.1) 343 (19.2)  140 (11.6) 
NTproBNP, pmol/L 
135 
(31-555) 
157 
(31-724) 
0.003 
112 
(29-354) 
Creatinine, µmol/L 
91  
(77-113) 
90  
(75-113) 
0.024 
92  
(78-113) 
eGFR, mL/min/1.73m² 70 (53-88) 71 (54-90) 0.001 69 (52-85) 
Sodium, mmol/L 139±9 139±11 0.013 139±5 
Potassium, mmol/L 4.4±0.5 4.3±0.5 0.004 4.4±0.5 
BUN, µmol/L 405 (321-500) 399 (315-506) 0.35 411 (327-494) 
TC, mmol/L  5.0±1.3  5.2±1.3 <0.001 4.8±1.3 
TC, n (%)   <0.001  
≤3.6 mg/dL 436 (14.6) 216 (12.1)  220 (18.2) 
3.7-4.9 mg/dL 1,058 (35.4) 570 (32.0)  488 (40.4) 
5.0-6.2 mg/dL 1,029 (34.4) 682 (38.3)  347 (28.7) 
>6.2 mg/dL 469 (15.7) 315 (17.7)  154 (12.7) 
Treatment     
Aspirin, n (%) 744 (24.9) 359 (20.1) <0.001 385 (31.8) 
ACEI, n (%) 2,111 (70.6) 1,238 (69.4) 0.10 873 (72.2) 
ACEI dose equivalent, 
% 
100 (50-100) 100 (50-100) 0.07 100 (50-100) 
ARB, n (%)  600 (20.1) 344 (19.3) 0.22 256 (21.2) 
ACEI and/or ARB, n 
(%) 
2,614 (87.4) 1,529 (85.8) 0.001 1,080 (89.3) 
ACEI/ARB dose 
equivalent, % 
75 (50-100) 62.5 (50-100) 0.06 75 (50-100) 
Beta blocker, n (%) 2,429 (81.2) 1,390 (78.0) <0.001 1,039 (85.9) 
Beta blocker dose 
equivalent, % 
53 (26-100) 53 (26-100) 0.054 53 (26-100) 
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Aldosterone antagonist, 
n (%) 
945 (31.6) 558 (31.3) 0.22 387 (32.1) 
Loop diuretic, n (%) 2,100 (70.2) 1,226 (68.8) 0.038 874 (72.3) 
Loop diuretic dose, mg 
furosemide 
40 (40-80) 40 (40-80) 0.51 40 (40-80) 
DCM, dilated cardiomyopathy; NYHA, New York Heart Association functional class; SBP, systolic blood pressure; HR, heart rate; BMI, 
body mass index; LVEF, left ventricular ejection fraction; aHT, arterial hypertension; COPD, chronic obstructive pulmonary disease; UK, 
United Kingdom; eGFR, estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation; BUN, blood urea 
nitrogen; TC, total serum cholesterol; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. Italic nnumbers 
indicate significant p-values (p<0.05). 
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Table 2: Baseline characteristics for matched patients and separate with respect to statin treatment 
Characteristic 
Matched patients  
(n=1,736) 
No statin  
(n=868) 
P-value Statin  
(n=868) 
Age, years 64.6±14.2 63.8±15.2 0.02 65.4±13.0 
Male, n (%) 1,188 (68.4) 581 (66.9) 0.18 607 (69.9) 
Aetiology, n (%)   0.89  
DCM 906 (52.2) 449 (51.7)  457 (52.6) 
Hypertensive 210 (12.1) 104 (12.0)  106 (12.2) 
Valvular 153 (8.8) 81 (9.3)  72 (8.3) 
Other 467 (26.9) 234 (27.0)  233 (26.8) 
NYHA, n (%)   0.05  
I 333 (19.2) 147 (16.9)  186 (21.4) 
II 914 (52.6) 483 (55.6)  431 (49.7) 
III 480 (27.6) 233 (26.8)  247 (31.6) 
IV 9 (0.5) 5 (0.6)  4 (0.5) 
SBP, mmHg 123±22 123±22 0.67 123±21 
HR, 1/min 70±14 70±14 0.87 70±13 
BMI, kg/m² 27.2±5.3 27.2±5.5 0.91 27.2±5.0 
LVEF, % 33±13 34±13 0.83 34±13 
Co-morbidity     
aHT, n (%) 799 (46.0) 392 (45.2) 0.47 407 (46.9) 
COPD, n (%) 277 (16.0) 139 (16.0) 0.95 138 (16.0) 
Diabetes, n (%) 273 (15.7) 134 (15.4) 0.74 139 (16.0) 
Smoker, n (%) 258 (14.9) 129 (14.9) 1.00 129 (14.9) 
Country, n (%)   0.03  
Norway 1,061 (61.1) 516 (59.4)  545 (62.8) 
Germany 455 (26.2) 224 (25.8)  231 (26.6) 
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UK 483 (12.7) 128 (14.7)  92 (10.6) 
NTproBNP, pmol/L 
128 
(35-475) 
152 
(43-607) 
0.004 
110 
(29-335) 
Creatinine, µmol/L 91 (78-114) 92 (78-117) 0.29 91 (77-111) 
eGFR, mL/min/1.73m² 69 (52-86) 69 (51-86) 0.48 70 (54-86) 
Sodium, mmol/L 139±3 139±3 1.00 139±3 
Potassium, mmol/L 4.4±0.5 4.4±0.5 0.59 4.4±0.4 
BUN, µmol/L 
406 
(327-500) 
405 
(327-506) 
0.94 
411 
(333-494) 
TC, mmol/L 4.9±1.2  4.9±1.2 0.97 4.9±1.2 
TC, n (%)   0.99  
≤3.6 mmol/L 274 (15.8) 139 (16.0)  135 (15.6) 
3.7-4.9 mmol/L 684 (39.4) 339 (39.1)  345 (39.7) 
4.9-6.2 mmol/L 549 (31.6) 276 (31.8)  273 (31.5) 
>6.2 mmol/L 229 (13.2) 114 (13.1)  115 (13.2) 
Treatment     
Aspirin, n (%) 502 (28.9) 246 (28.3) 0.60 256 (29.5) 
ACEI, n (%) 1,315 (75.7) 661 (76.2) 0.70 654 (75.3) 
ACEI dose equivalent, 
% 
100 (50-100) 100 (50-100) 0.84 100 (50-100) 
ARB, n (%)  351 (20.2) 173 (19.9) 0.77 178 (20.5) 
ACEI and/or ARB, n 
(%) 
1,602 (92.3) 809 (93.2) 0.31 798 (91.9) 
ACEI/ARB dose 
equivalent, % 
100 (50-100) 100 (50-100) 0.74 100 (50-100) 
Beta blocker, n (%) 1,524 (87.8) 767 (88.4) 0.46 757 (87.2) 
Beta blocker dose 
equivalent, % 
53 (26-100) 53 (26-100) 0.28 53 (38-100) 
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Aldosterone antagonist, 
n (%) 
586 (33.8) 297 (34.2) 0.66 289 (33.3) 
Loop diuretic, n (%) 1,265 (72.9) 635 (73.2) 0.79 630 (72.6) 
Loop diuretic dose, mg 
furosemide 
40 (40-80) 40 (40-80) 0.68 40 (40-80) 
DCM, dilated cardiomyopathy; NYHA, New York Heart Association functional class; SBP, systolic blood pressure; HR, heart rate; BMI, 
body mass index; LVEF, left ventricular ejection fraction; aHT, arterial hypertension; COPD, chronic obstructive pulmonary disease; UK, 
United Kingdom; eGFR, estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation; BUN, blood urea 
nitrogen; TC, total serum cholesterol; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. Italic numbers 
indicate significant p-values (p<0.05). 
 
 
 
